Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

Massimo Breccia, Claudia Baratè, Giulia Benevolo, Massimiliano Bonifacio, Elena Maria Elli, Paola Guglielmelli, Margherita Maffioli, Alessandra Malato, Francesco Mendicino, Giuseppe Alberto Palumbo, Novella Pugliese, Elena Rossi, Elisa Rumi, Emanuela Sant’Antonio, Alessandra Ricco, Mario Tiribelli, Francesca Palandri

Research output: Contribution to journalArticlepeer-review

Abstract

The management of patients with myelofibrosis (MF) has dramatically changed since the introduction of ruxolitinib as a tailored treatment strategy. However, the perceptions about the use of this drug in clinical practice remain, at times, a matter of discussion. We conducted a survey about the diagnostic evaluation, prognostic assessment, and management of ruxolitinib in real-life clinical practice in 18 Italian hematology centers. At diagnosis, most hematologists do not use genetically or molecularly inspired score systems to assess prognosis, mainly due to scarce availability of next-generation sequencing (NGS) methodology, with NGS conversely reserved only for a subset of lower-risk MF patients with the aim of possibly improving the treatment strategy. Some common points in the management of ruxolitinib were 1) clinical triggers for ruxolitinib therapy, regardless of risk category; 2) evaluation of infectious risk before the starting of the drug; and 3) schedule of monitoring during the first 12 weeks with the need, in some instances, of supportive treatment. Further development of international recommendations and insights will allow the achievement of common criteria for the management of ruxolitinib in MF, before and after treatment, and for the definition of response and failure.

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • Myelofibrosis
  • Real-life practice
  • Ruxolitinib
  • Survey
  • Therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice'. Together they form a unique fingerprint.

Cite this